Altimmune, a clinical-stage biopharmaceutical company, and Switzerland-based Lonza, a global partner to the pharmaceutical, biotech, and nutrition markets, extended their AdCOVID manufacturing collaboration. Per the terms of the extended agreement, clinical and commercial production of AdCOVID, Altimmune’s (ALT) single-dose intranasal vaccine candidate for COVID-19, will be supported by Lonza with a committed manufacturing suite at the company’s facility near Houston, Texas. Altimmune VP of Product Development Dr. Vyjayanthi Krishnan said, “Manufacturing capacity for COVID-19 vaccines has been severely constrained, and this limitation has presented considerable challenges for vaccine developers.